{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:02:14Z","timestamp":1789498934285,"version":"build-2803163510"},"reference-count":100,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.drudis.2025.104543","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T10:10:17Z","timestamp":1763374217000},"page":"104543","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["siRNA-based Nanocarriers for Targeted Therapy in Prostate Cancer: Implications for Male Fertility Preservation"],"prefix":"10.1016","volume":"30","author":[{"given":"Krishna Kant","family":"Jangde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh Kumar","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradyumna Kumar","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2025.104543_b0005","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.3390\/cancers14122954","article-title":"A Tale of two cancers: a current concise overview of breast and prostate cancer","volume":"14","author":"De Silva","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.drudis.2025.104543_b0010","series-title":"The Prostate Gland. Basics of Human Andrology","first-page":"17","author":"Sharma","year":"2017"},{"key":"10.1016\/j.drudis.2025.104543_b0015","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.urology.2011.07.1395","article-title":"The McNeal prostate: a review","volume":"78","author":"Selman","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.drudis.2025.104543_b0020","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eururo.2022.04.002","article-title":"Management of patients with advanced prostate cancer: report from the Advanced Prostate Cancer Consensus Conference 2021","volume":"82","author":"Gillessen","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.drudis.2025.104543_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.100962","article-title":"Current therapy and drug resistance in metastatic castration-resistant prostate cancer","volume":"68","author":"Cai","year":"2023","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drudis.2025.104543_b0030","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70979","article-title":"Understanding racial disparities in prostate cancer: a multifaceted approach","volume":"14","author":"Cobbs","year":"2025","journal-title":"Cancer Med"},{"key":"10.1016\/j.drudis.2025.104543_b0035","doi-asserted-by":"crossref","first-page":"598","DOI":"10.4103\/ijmr.ijmr_1821_22","article-title":"Cancer incidence estimates for 2022 & projection for 2025","volume":"156","author":"Sathishkumar","year":"2022","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.drudis.2025.104543_b0040","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/s12885-024-12041-y","article-title":"Rural-urban disparity in cancer burden and care: findings from an Indian cancer registry","volume":"24","author":"Khanna","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.drudis.2025.104543_b0045","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/ng.371","article-title":"Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis","volume":"41","author":"King","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.drudis.2025.104543_b0050","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1208\/s12248-016-0016-x","article-title":"Epigenetic CpG methylation of the promoter and reactivation of the expression of GSTP1 by astaxanthin in human prostate LNCaP cells","volume":"19","author":"Yang","year":"2017","journal-title":"AAPS J"},{"key":"10.1016\/j.drudis.2025.104543_b0055","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.pharmthera.2013.07.003","article-title":"Androgen receptors in hormone-dependent and castration-resistant prostate cancer","volume":"140","author":"Shafi","year":"2013","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.drudis.2025.104543_b0060","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.acuro.2013.04.008","article-title":"Clinical significance of proliferative inflammatory atrophy in prostate biopsy","volume":"38","author":"Celma","year":"2014","journal-title":"Actas Urol\u00f3gicas Espa\u00f1olas"},{"key":"10.1016\/j.drudis.2025.104543_b0065","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1126\/science.1117679","article-title":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer","volume":"310","author":"Tomlins","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.drudis.2025.104543_b0070","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/nature11674","article-title":"COUP-TFII inhibits TGF-\u03b2-induced growth barrier to promote prostate tumorigenesis","volume":"493","author":"Qin","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2025.104543_b0075","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1159\/000019778","article-title":"p53 tumour suppressor gene mutations in benign prostatic hyperplasia and prostate cancer","volume":"34","author":"Schlechte","year":"1998","journal-title":"Eur Urol"},{"key":"10.1016\/j.drudis.2025.104543_b0080","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/pcan.2010.31","article-title":"Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence","volume":"13","author":"Hawksworth","year":"2010","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.drudis.2025.104543_b0085","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"31","author":"Castro","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2025.104543_b0090","doi-asserted-by":"crossref","unstructured":"Lingadahalli S, et al. HOXB13 alters chromatin accessibility in prostate cancer through interactions with the SWI\/SNF complex. bioRxiv. Published online September 5, 2023. https:\/\/doi.org\/10.1101\/2023.09.04.556101.","DOI":"10.1101\/2023.09.04.556101"},{"key":"10.1016\/j.drudis.2025.104543_b0095","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev.med.60.042307.110714","article-title":"Biomarkers for prostate cancer","volume":"60","author":"Makarov","year":"2009","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.drudis.2025.104543_b0100","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1023\/A:1026057402945","article-title":"The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer","volume":"253","author":"Chatterjee","year":"2003","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.drudis.2025.104543_b0105","doi-asserted-by":"crossref","first-page":"11034","DOI":"10.3390\/ijms140611034","article-title":"Current status of biomarkers for prostate cancer","volume":"14","author":"Velonas","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104543_b0110","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1158\/0008-5472.CAN-10-2665","article-title":"Endoglin regulates cancer\u2013stromal cell interactions in prostate tumors","volume":"71","author":"Romero","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2025.104543_b0115","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/PAP.0000000000000422","article-title":"DNA damage response and mismatch repair gene defects in advanced and metastatic prostate Cancer","volume":"31","author":"Akhoundova","year":"2024","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.drudis.2025.104543_b0120","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/1479-5876-11-111","article-title":"SATB1 is overexpressed in metastatic prostate cancer and promotes prostate cancer cell growth and invasion","volume":"11","author":"Mao","year":"2013","journal-title":"J Transl Med"},{"key":"10.1016\/j.drudis.2025.104543_b0125","doi-asserted-by":"crossref","first-page":"25872","DOI":"10.1074\/jbc.M301744200","article-title":"Bcl-xL mediates a survival mechanism independent of the phosphoinositide 3-kinase\/Akt pathway in prostate cancer cells","volume":"278","author":"Yang","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2025.104543_b0130","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/j.bbamcr.2009.11.001","article-title":"TRIM24 mediates ligand-dependent activation of androgen receptor and is repressed by a bromodomain-containing protein, BRD7, in prostate cancer cells","volume":"1793","author":"Kikuchi","year":"2009","journal-title":"Biochimica et Biophysica Acta (BBA) \u2013 Mol Cell Res"},{"key":"10.1016\/j.drudis.2025.104543_b0135","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.18632\/oncotarget.2127","article-title":"Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands","volume":"5","author":"De","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.drudis.2025.104543_b0140","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1677\/erc.1.00728","article-title":"Hypoxia-inducible factor-1 in human breast and prostate cancer","volume":"13","author":"Kimbro","year":"2006","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.drudis.2025.104543_b0145","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.eururo.2016.08.037","article-title":"DNA repair in prostate cancer: biology and clinical implications","volume":"71","author":"Mateo","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.drudis.2025.104543_b0150","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10565-025-10046-2","article-title":"ADT increases prostate cancer cell invasion via altering AR\/SALL4\/SOX2-OCT4 stem cell signaling","volume":"41","author":"Guo","year":"2025","journal-title":"Cell Biol Toxicol"},{"key":"10.1016\/j.drudis.2025.104543_b0155","doi-asserted-by":"crossref","first-page":"171","DOI":"10.5489\/cuaj.2806","article-title":"Active surveillance for the management of localized prostate cancer: guideline recommendations","volume":"9","author":"Morash","year":"2015","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.drudis.2025.104543_b0160","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1111\/j.1743-6109.2011.02215.x","article-title":"Randomized comparison between laparoscopic and robot-assisted nerve-sparing radical prostatectomy","volume":"8","author":"Asimakopoulos","year":"2011","journal-title":"J Sex Med"},{"key":"10.1016\/j.drudis.2025.104543_b0165","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/COC.0000000000000796","article-title":"Patient-reported quality of life after SBRT, LDR, and HDR brachytherapy for prostate cancer","volume":"44","author":"Paly","year":"2021","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.drudis.2025.104543_b0170","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_433126","article-title":"Balancing hormone therapy: mitigating adverse effects of androgen-deprivation therapy and exploring alternatives in prostate cancer management","volume":"44","author":"Gudenkauf","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.drudis.2025.104543_b0175","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrurol.2013.274","article-title":"CYP17 inhibitors\u2014abiraterone, C17,20-lyase inhibitors and multi-targeting agents","volume":"11","author":"Yin","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.drudis.2025.104543_b0180","doi-asserted-by":"crossref","first-page":"436","DOI":"10.21037\/tau.2018.02.07","article-title":"Radium and other alpha emitters in prostate cancer","volume":"7","author":"Sartor","year":"2018","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.drudis.2025.104543_b0185","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ctrv.2017.04.008","article-title":"Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer","volume":"57","author":"Galletti","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.drudis.2025.104543_b0190","doi-asserted-by":"crossref","first-page":"13519","DOI":"10.3390\/ijms222413519","article-title":"An insight on novel molecular pathways in metastatic prostate cancer: a focus on DDR, MSI and AKT","volume":"22","author":"Mollica","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104543_b0195","doi-asserted-by":"crossref","first-page":"300","DOI":"10.4161\/epi.3.6.7273","article-title":"The role of histone deacetylases in prostate cancer","volume":"3","author":"Abbas","year":"2008","journal-title":"Epigenetics"},{"key":"10.1016\/j.drudis.2025.104543_b0200","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.991330","article-title":"Advances and development of prostate cancer, treatment, and strategies: a systemic review","volume":"10","author":"Belkahla","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.drudis.2025.104543_b0205","first-page":"1","article-title":"Recent developments in nanoparticle-based siRNA delivery for cancer therapy","volume":"2013","author":"Lee","year":"2013","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.drudis.2025.104543_b0210","doi-asserted-by":"crossref","first-page":"11571","DOI":"10.1007\/s13277-014-2462-3","article-title":"Down-regulation of Dicer and Ago2 is associated with cell proliferation and apoptosis in prostate cancer","volume":"35","author":"Bian","year":"2014","journal-title":"Tumor Biol"},{"key":"10.1016\/j.drudis.2025.104543_b0215","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2174\/156800909787580999","article-title":"Targeted therapy for advanced prostate cancer: inhibition of the PI3K\/Akt\/mTOR pathway","volume":"9","author":"Morgan","year":"2009","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.drudis.2025.104543_b0220","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.2217\/fon-2023-0227","article-title":"siRNA-based approaches for castration-resistant prostate cancer therapy targeting the androgen receptor signaling pathway","volume":"19","author":"Yu","year":"2023","journal-title":"Future Oncol"},{"key":"10.1016\/j.drudis.2025.104543_b0225","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.clgc.2023.12.008","article-title":"Oral toxicities of PSMA-targeted immunotherapies for the management of prostate cancer","volume":"22","author":"Emperumal","year":"2024","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.drudis.2025.104543_b0230","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.3390\/ijms22084109","article-title":"Immune checkpoints, inhibitors and radionuclides in prostate cancer: promising combinatorial therapy approach","volume":"22","author":"Kgatle","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104543_b0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11523-023-01016-x","article-title":"Hematological toxicity of PARP inhibitors in metastatic prostate cancer patients with mutations of BRCA or HRR genes: a systematic review and safety meta-analysis","volume":"19","author":"Maiorano","year":"2024","journal-title":"Target Oncol"},{"key":"10.1016\/j.drudis.2025.104543_b0240","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1016\/j.matt.2022.04.032","article-title":"Transforming \u2018cold\u2019 tumors into \u2018hot\u2019 ones via tumor-microenvironment-responsive siRNA micelleplexes for enhanced immunotherapy","volume":"5","author":"Yi","year":"2022","journal-title":"Matter"},{"key":"10.1016\/j.drudis.2025.104543_b0245","first-page":"62","article-title":"Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA","volume":"1","author":"Wang","year":"2009","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.drudis.2025.104543_b0250","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.3390\/cancers12123619","article-title":"Advances in targeting cancer-associated genes by designed siRNA in prostate cancer","volume":"12","author":"Bahreyni","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.drudis.2025.104543_b0255","first-page":"1","article-title":"Recent developments in nanoparticle-based siRNA delivery for cancer therapy","volume":"2013","author":"Lee","year":"2013","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.drudis.2025.104543_b0260","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3390\/bioengineering7030091","article-title":"Progress in delivery of siRNA-based therapeutics employing nano-vehicles for treatment of prostate cancer","volume":"7","author":"Ashrafizadeh","year":"2020","journal-title":"Bioengineering"},{"key":"10.1016\/j.drudis.2025.104543_b0265","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.2147\/IJN.S129574","article-title":"Enhancing siRNA-based cancer therapy using a new pH-responsive activatable cell-penetrating peptide-modified liposomal system","volume":"12","author":"Xiang","year":"2017","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.drudis.2025.104543_b0270","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40259-025-00711-7","article-title":"The fomivirsen, patisiran, and givosiran odyssey: how the success stories may pave the way for future clinical translation of nucleic acid drugs","volume":"39","author":"Mansouri","year":"2025","journal-title":"BioDrugs"},{"key":"10.1016\/j.drudis.2025.104543_b0275","first-page":"142","article-title":"Functionalized nanoparticles targeting biomarkers for prostate cancer imaging and therapy","volume":"10","author":"Choksi","year":"2022","journal-title":"Am J Clin Exp Urol"},{"key":"10.1016\/j.drudis.2025.104543_b0280","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12943-023-01849-0","article-title":"Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics","volume":"22","author":"Gajbhiye","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.drudis.2025.104543_b0285","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2024.1447953","article-title":"Exosome-mediated delivery of siRNA molecules in cancer therapy: triumphs and challenges","volume":"11","author":"Ubanako","year":"2024","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.drudis.2025.104543_b0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2019.12.005","article-title":"Exosome-mediated siRNA delivery to suppress postoperative breast cancer metastasis","volume":"318","author":"Zhao","year":"2020","journal-title":"J Control Release"},{"key":"10.1016\/j.drudis.2025.104543_b0295","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/cmdc.200900444","article-title":"Exploring chemical modifications for siRNA therapeutics: a structural and functional outlook","volume":"5","author":"Shukla","year":"2010","journal-title":"ChemMedChem"},{"key":"10.1016\/j.drudis.2025.104543_b0300","doi-asserted-by":"crossref","first-page":"7498","DOI":"10.1038\/s41598-018-25930-7","article-title":"PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer","volume":"8","author":"Risnayanti","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2025.104543_b0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcmd.2006.10.003","article-title":"RNA targeting with peptide conjugates of oligonucleotides, siRNA and PNA","volume":"38","author":"Turner","year":"2007","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.drudis.2025.104543_b0310","doi-asserted-by":"crossref","first-page":"4348","DOI":"10.1016\/j.biomaterials.2008.07.036","article-title":"Self-assembled biodegradable micellar nanoparticles of amphiphilic and cationic block copolymer for siRNA delivery","volume":"29","author":"Sun","year":"2008","journal-title":"Biomaterials"},{"key":"10.1016\/j.drudis.2025.104543_b0315","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1021\/acs.molpharmaceut.8b01307","article-title":"Self-assembled cationic \u03b2-cyclodextrin nanostructures for siRNA delivery","volume":"16","author":"Singh","year":"2019","journal-title":"Mol Pharm"},{"key":"10.1016\/j.drudis.2025.104543_b0320","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/iju5.12176","article-title":"Testicular sperm extraction in a patient with ejaculatory dysfunction after combined androgen blockade therapy for prostate cancer","volume":"3","author":"Amano","year":"2020","journal-title":"IJU Case Rep"},{"key":"10.1016\/j.drudis.2025.104543_b0325","article-title":"Delivery of EGFR-siRNA to prostatic cancerous cells based on polydopamine coated gold nanoparticles","volume":"87","author":"Heris","year":"2023","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.drudis.2025.104543_b0330","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.msec.2019.02.026","article-title":"Magnetically responsive hybrid nanoparticles for in vitro siRNA delivery to breast cancer cells","volume":"99","author":"Dalmina","year":"2019","journal-title":"Mater Sci Eng C"},{"key":"10.1016\/j.drudis.2025.104543_b0335","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1021\/mp5006883","article-title":"Codelivery of DNA and siRNA via arginine-rich PEI-based polyplexes","volume":"12","author":"Lu","year":"2015","journal-title":"Mol Pharm"},{"key":"10.1016\/j.drudis.2025.104543_b0340","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ijpharm.2018.05.045","article-title":"Poly (amidoamine) (PAMAM) dendrimer mediated delivery of drug and pDNA\/siRNA for cancer therapy","volume":"546","author":"Li","year":"2018","journal-title":"Int J Pharm"},{"key":"10.1016\/j.drudis.2025.104543_b0345","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1049\/mna2.12133","article-title":"Synthesis of echogenic liposomes for sonoporation","volume":"17","author":"Park","year":"2022","journal-title":"Micro Nano Lett"},{"key":"10.1016\/j.drudis.2025.104543_b0350","first-page":"292","article-title":"Lipid nanoparticle delivery of mRNA and siRNA for concurrent restoration of tumor suppressor and inhibition of tumorigenic driver in prostate cancer","volume":"5","author":"Farokhzad","year":"2024","journal-title":"ACS Nanosci Au"},{"key":"10.1016\/j.drudis.2025.104543_b0355","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1657040","article-title":"Gene expression silencing therapy in tumors, focus on gastrointestinal and genitourinary tumors","volume":"16","author":"El-Ghazzi","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2025.104543_b0360","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3390\/jpm15080360","article-title":"Prostate cancer treatments and their effects on male fertility: mechanisms and mitigation strategies","volume":"15","author":"Kaltsas","year":"2025","journal-title":"J Pers Med"},{"key":"10.1016\/j.drudis.2025.104543_b0365","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/andr.13729","article-title":"Engineered nanoparticles potentials in male reproduction","volume":"13","author":"Zhao","year":"2025","journal-title":"Andrology"},{"key":"10.1016\/j.drudis.2025.104543_b0370","doi-asserted-by":"crossref","first-page":"9143","DOI":"10.3390\/ijms25179143","article-title":"The interplay between autophagy and mitochondria in cancer","volume":"25","author":"Zdanowicz","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104543_b0375","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.877537","article-title":"Fertility preservation and restoration options for pre-pubertal male cancer patients: current approaches","volume":"13","author":"Eugeni","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.drudis.2025.104543_b0380","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.3390\/pharmaceutics13071009","article-title":"Clinical advances of siRNA-based nanotherapeutics for cancer treatment","volume":"13","author":"Hattab","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2025.104543_b0385","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/978-1-4939-9220-1_21","article-title":"Bioconjugated gold nanoparticles enhance siRNA delivery in prostate cancer cells","volume":"1974","author":"Rahme","year":"2019","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.drudis.2025.104543_b0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.129233","article-title":"Tumor-targeted delivery of SNHG15 siRNA using a ZIF-8 nanoplatform: towards a more effective prostate cancer therapy","volume":"259","author":"Saeinasab","year":"2024","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.drudis.2025.104543_b0395","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1021\/acsnanoscienceau.4c00066","article-title":"Lipid nanoparticle delivery of mRNA and siRNA for concurrent restoration of tumor suppressor and inhibition of tumorigenic driver in prostate cancer","volume":"5","author":"Farokhzad","year":"2024","journal-title":"ACS Nanosci Au"},{"key":"10.1016\/j.drudis.2025.104543_b0400","doi-asserted-by":"crossref","first-page":"152","DOI":"10.7150\/ntno.79050","article-title":"Gold nanoparticles conjugated with dendrigraft poly-L-lysine and folate-targeted poly(ethylene glycol) for siRNA delivery to prostate cancer","volume":"7","author":"Minassian","year":"2023","journal-title":"Nanotheranostics"},{"key":"10.1016\/j.drudis.2025.104543_b0405","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1002\/cncr.34916","article-title":"Outcomes after definitive radiation therapy for localized prostate cancer in a national healthcare delivery system","volume":"129","author":"Herr","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.drudis.2025.104543_b0410","doi-asserted-by":"crossref","first-page":"6408","DOI":"10.1002\/jcp.26593","article-title":"Nanoparticle-based targeted cancer strategies for non-invasive prostate cancer intervention","volume":"233","author":"Farina","year":"2018","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.drudis.2025.104543_b0415","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.3390\/pharmaceutics13071009","article-title":"Clinical advances of siRNA-based nanotherapeutics for cancer treatment","volume":"13","author":"Hattab","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2025.104543_b0420","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS2604","article-title":"EphA2 gene targeting using neutral liposomal small interfering RNA (EPHARNA) delivery: a phase I clinical trial","volume":"35","author":"Naing","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2025.104543_b0425","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1089\/nat.2023.0068","article-title":"Nucleic acid therapeutics: successes, milestones, and upcoming innovation","volume":"34","author":"Belgrad","year":"2024","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.drudis.2025.104543_b0430","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1007\/s00259-025-07131-3","article-title":"Comparison of 64Cu-DOTA-PSMA-3Q and 64Cu-NOTA-PSMA-3Q utilizing NOTA and DOTA as bifunctional chelators in prostate cancer: preclinical assessment and preliminary clinical PET\/CT imaging","volume":"52","author":"Liu","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.drudis.2025.104543_b0435","doi-asserted-by":"crossref","first-page":"18590","DOI":"10.1073\/pnas.1906929116","article-title":"Gold nanoshell-localized photothermal ablation of prostate tumors in a clinical pilot device study","volume":"116","author":"Rastinehad","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2025.104543_b0440","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.ijrobp.2022.07.353","article-title":"3-dimensional volumetric distribution and dispersion analysis of the radioenhancer NBTXR3 in various solid malignancies","volume":"114","author":"Shen","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.drudis.2025.104543_b0445","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2174\/138920012798356899","article-title":"The ligand nanoparticle conjugation approach for targeted cancer therapy","volume":"13","author":"Karra","year":"2011","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.drudis.2025.104543_b0450","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1158\/1078-0432.CCR-15-0866","article-title":"siRNA lipid nanoparticle potently silences clusterin and delays progression when combined with androgen receptor cotargeting in enzalutamide-resistant prostate cancer","volume":"21","author":"Yamamoto","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2025.104543_b0455","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/4719790","article-title":"Efficient delivery of therapeutic siRNA with nanoparticles induces apoptosis in prostate cancer cells","volume":"2018","author":"Mu","year":"2018","journal-title":"J Nanomater"},{"key":"10.1016\/j.drudis.2025.104543_b0460","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/978-1-4939-9220-1_21","article-title":"Bioconjugated gold nanoparticles enhance siRNA delivery in prostate cancer cells","volume":"1974","author":"Rahme","year":"2019","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.drudis.2025.104543_b0465","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.3390\/pharmaceutics15071899","article-title":"Recent advances in cell membrane coated-nanoparticles as drug delivery systems for tackling urological diseases","volume":"15","author":"Yao","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2025.104543_b0470","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jconrel.2022.06.051","article-title":"Lipid nanoparticles to silence androgen receptor variants for prostate cancer therapy","volume":"349","author":"Quick","year":"2022","journal-title":"J Control Release"},{"key":"10.1016\/j.drudis.2025.104543_b0475","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3892\/wasj.2025.313","article-title":"Recent advancements in therapeutic biomarkers, associated challenges and considerations to overcome these challenges in prostate cancer (review)","volume":"7","author":"Gandupalli","year":"2025","journal-title":"World Acad Sci J"},{"key":"10.1016\/j.drudis.2025.104543_b0480","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2174\/1389201022666210615123211","article-title":"Recent advances in siRNA delivery systems for prostate cancer therapy","volume":"23","author":"Aghamiri","year":"2022","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/j.drudis.2025.104543_b0485","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.3390\/cancers17071064","article-title":"Immunotherapy in prostate cancer: from a \u2018cold\u2019 tumor to a \u2018hot\u2019 prospect","volume":"17","author":"Kwon","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.drudis.2025.104543_b0490","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/pcan.2016.17","article-title":"Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting","volume":"19","author":"Antonarakis","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.drudis.2025.104543_b0495","doi-asserted-by":"crossref","first-page":"9529","DOI":"10.1007\/s11033-023-08749-y","article-title":"Advances in siRNA delivery approaches in cancer therapy: challenges and opportunities","volume":"50","author":"Isazadeh","year":"2023","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.drudis.2025.104543_b0500","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.3389\/fonc.2019.01263","article-title":"A new era of prostate cancer precision medicine","volume":"9","author":"Malik","year":"2019","journal-title":"Front Oncol"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625002569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625002569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:12:39Z","timestamp":1780920759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644625002569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":100,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1359644625002569"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104543","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"siRNA-based Nanocarriers for Targeted Therapy in Prostate Cancer: Implications for Male Fertility Preservation","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104543","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104543"}}